News on Pfizer (Ticker: PFE) continually updated from thousands of sources around the net.
29 min ago | Vallejo Times-Herald
Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.
29 min ago | WTHR-TV Indianapolis
Most of the 1,200 people driven to evacuate by a Northern California wildfire that destroyed 13 homes have been told they can safely return after a series of steady gains in the firefight.
29 min ago | Customer Interaction Solutions
Pfizer Inc. reported financial results for second-quarter 2014. At the beginning of fiscal year 2014, the company began managing its commercial operations through a new global commercial structure consisting of three operating segments: the Global Innovative Pharmaceutical segment ; the Global Vaccines, Oncology and Consumer Healthcare segment ; ... (more)
1 hr ago | The Globe and Mail
The Pfizer logo on the exterior of a former Pfizer factory, in the Brooklyn borough of New York, on May 4, 2014.
The East Side towers of the Alexandria Center for Life Science have attracted giant pharmaceutical companies such as Pfizer Inc. and Eli Lilly & Co.
When Provectus Biopharmaceuticals Inc. announced at the end of May that the FDA had denied it Breakthrough Therapy Designation it caused a sharp drop in the stock price.
Pfizer has a 59% positive surprise history . The overall average post earnings price move is 'positive' when the company reports earnings.
So concludes BMO Capital Markets today in a downgrade report, which sent shares of Pfizer down nearly 1% to $29.86.
Consistently, one of the more popular stocks people enter into their stock options watchlist at Stock Options Channel is Pfizer Inc .
Separately, TheStreet Ratings team rates PFIZER INC as a "buy" with a ratings score of B. TheStreet Ratings Team has this to say about their recommendation: "We rate PFIZER INC a BUY.
Pfizer Inc's vulnerability to cheaper generics and its weak roster of experimental medicines will be on display Tuesday when the company reports quarterly earnings, reviving interest in its pursuit of AstraZeneca Plc or other deals to fortify its pipeline.
Alan Auerbach specializes in testing drugs that Big Pharma doesn't want anymore, and that has made him a billionaire.
JNJ reported a 2.4% increase in its consumer segment revenue, led by a 9% rise from over the counter drugs, including Tylenol.
This Eye-Popping Chart Of Ex-US Companies Shows Why People Are Freaking Out About 'Tax Inversions' A tax inversion is a corporate merger strategy that involves a company based in one country, say the U.S., acquires another company based somewhere else, say the U.K., and following the deal moves its tax base to enjoy a lower corporate tax rate.
Updated: Tue Jul 29, 2014 05:49 am
Copyright © 2014 Topix LLC